Research
Hormonal
Gut microbiota dysbiosis, specifically involving Escherichia Coli producing the CIpB protein, may contribute to eating disorder pathology by mimicking satiety hormones and triggering autoimmune reactions.
Current research suggests gut health may play a role in eating disorders, but it is not yet a primary treatment target. Focus on established treatments like nutritional rehabilitation and therapy. Future probiotics or microbiome-targeted therapies may emerge, but are not currently standard care.
ModerateQualifiesMEDIUM confidence
The CIpB protein has a similar structure to the human hormone responsible for simulating secretion of satiation peptide YY... Intestinal infections and chronic inflammation can lead to large increases in the number of E. coli bacteria in the GI tract, therefore increasing the levels of peptide YY and potentially increasing risk of ED
Why this rating
Based on observational studies and murine models, lacking large-scale human causal evidence.
Source
Risk factors for eating disorders: findings from a rapid review
Sarah Barakat et al. · Journal of Eating Disorders · 2023
DOI 10.1186/s40337-022-00717-4
narrative_reviewCited 311×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Genetic factors, particularly polymorphisms affecting neurotransmitter systems (dopamine, serotonin) and metabolic traits (BMI, insulin resistance), significantly increase the risk of developing eating disorders, with distinct genetic architectures for anorexia nervosa versus binge-type disorders.Good
- Childhood trauma, abuse, and neglect are strongly linked to the development of eating disorders, particularly Bulimia Nervosa and Binge Eating Disorder, through interactions with genetic susceptibility.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →